Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do

FDA's three-month postponement of a decision on AstraZeneca PLC’s NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.